BioWorld

Dec. 22, 2006

GSK Buying Praecis For $55M, Gaining Cancer Drug, PPI-2458

Continuing a late-year spending spree for biotech, GlaxoSmithKline plc is acquiring Praecis Pharmaceuticals Inc. in a cash deal valued at about $54.8 million. (BioWorld Today) Read More

Genzyme Submitting NDA For Renvela, Eying Broader Sales

Exclusive Club' Of Noncoding RNA Now Open To 21U Crowd

Industry Mulling Movement Toward Price Transparency

Holiday Notice

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Businesswoman pressing dollar sign on touchscreen

JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

BioWorld

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...